A randomized, open-label, Phase 2/3 study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus gemcitabine plus Carboplatin or Cisplatin in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) that progressed during or after enfortumab vedotin (EV) plus combination therapy with Pembrolizumab.
Contact Information for Access
Status
IN ATTIVAZIONE
Objective of the study
To evaluate the relative efficacy of Dato-DXd 4 mg/kg in combination with platinum-based therapy compared with Dato-DXd 6 mg/kg in combination with platinum-based therapy, as measured by the objective response rate (ORR) assessed by the investigator.
Urothelial Carcinoma
Medication
Datopotamab Deruxtecan + Carboplatin or Cisplatin vs. Gemcitabine + Carboplatin or Cisplatin
Who is eligible to participate in the study?
Patients who are 18 years of age or older and meet the study’s eligibility criteria may participate in this study.
Patients with urothelial carcinoma following combination therapy with Enfortumab Vedotin (EV) + Pembrolizumab
Back to search page